Finovam Gestion
VC Fund
Villeneuve, France
Finovam Gestion is an investment company approved by the AMF which takes minority stakes in innovative SMEs with high growth potential.The company, which manages €50M, invests in companies that have developed innovative offers in the following target sectors: Information and Communication Technology, Health and Biotechnologies, Agro-resources andEcotechnologies.Finovam Gestion has built solid relationships with the ecosystem of entrepreneurship (Industrials, Poles of Competitiveness, Incubators, Accelerators, Universities, and Research Centers) in all the sectors that we target in order to be able to source and do emerge the best companies.Among our investors (LPs), we can count BPI France, manufacturers (ADEO, LESAFFRE, TEREOS), banks (BNP Paribas, Caisse d´Epargne, Crédit Agricole) and the Haut de France and Grand-Est regions.
- Total investments:
- 44
- Last investment:
- Lead investor:
- 30%
Last updated:
For AI agents: llms.txt
Industries Finovam Gestion invests in
Stages Finovam Gestion invests in
Countries Finovam Gestion invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $513k–$3.4M
- Series A
- $530k–$18M
Investment Focus
Industry
- Software 9 (20%)
- Information Technology 7 (16%)
- Medical 5 (11%)
- Medical Device 5 (11%)
- Health Care 4 (9%)
Stage
- Seed 23 (52%)
- Series A 8 (18%)
- Funding Round 3 (7%)
- Venture - Series Unknown 3 (7%)
- Pre-Seed 2 (5%)
Country
- France 34 (77%)
- United States 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Anthony Daccache
Seed Capital Developer - Seed Investment Fund
|
Seed Capital Developer - Seed Investment Fund | Total investments: 1 | Find email | |
Hélène Cannard
Member of executive management
|
Member of executive management | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Today 1 women on 8 has a breast cancer, 40% of them will have a mastectomy to cure cancer and only 14% of them will have reconstruction because actual technics does no fit for breast reconstruction. That’s why LATTICE MEDICAL develops the implantable device MATTISSE which answer to clinical and societal issues and allow women to get back theirbodies and life. MATTISSE implant allows a natural reconstruction by regenerating autologous adipose tissues, custom reconstruction thanks to 3D printing and single surgery due to fully biodegradable material, which fully disappear after reconstruction. We aim in long term to replace silicon-based implant by our technology. | $50M / Series B / Oct 24, 2025 | ||
| StemInov is a biotechnology company that focuses on the development of stem cell therapies for inflammatory diseases. The company's primary focus is on critical care, specifically septic shock and Acute Respiratory Distress Syndrome (ARDS). StemInov's approach is based on robust preclinical data and widely accepted safety measures. Thecompany is developing an off-the-shelf and allogenic cell therapy. StemInov is also working on a drug-based therapy using mesenchymatous stem cells from Wharton's jelly (WJ-MSC). | $12.4M / Series A / Sep 25, 2025 | ||
| Pikkopay provides a mobile payment solution that transforms customer smartphones into cash registers. Customers can scan items, pay, and go, eliminating the need for traditional checkout lines. The service aims to streamline the shopping experience and increase user retention rates. Pikkopay is designed to save time for both customers andretailers, offering a hassle-free shopping experience. | $1.8M / Seed / Sep 23, 2025 | ||
| Dianosic was founded in 2017 and develops innovative solutions in the field of ENT (Ear, Nose & Throat), a $50 billion, double digit growth, and still largely underserved market. Our startup operates right at the frontier between Medtech and Biotech, as we see tremendous opportunities for drug-device combinations in this specialty. The projectoriginates from the ENT Department from the University Hospital of Strasbourg, where unmet clinical needs have been identified. Our main focus areas are Chronic Rhinitis, Chronic Sinusitis and intranasal bleeding (Epistaxis). Noteworthy, Dianosic has a strong French and German footprint in R&D and manufacturing.Dianosic’s strategic goal is to establish new standards of care in Chronic Rhinitis and Chronic Sinusitis with its drug-eluting Active Resorbable Scaffold (ARIS). This drug-device combination ARIS platform, developed with world renowned resorbable polymers experts, has the potential to establish new treatment paradigms. Moreover, our ARIS platform creates immense opportunities to create other verticals, especially in the field of chronic migraine and facial pain.Beside this, Dianosic commercialize an Asymmetric Intranasal inflatable solution (CAVI-T) for the treatment of intranasal bleeding, a widespread condition in ENT that affects 10% of the population. This CE marked and FDA registered technology addresses a clear unmet need and demonstrated our ability not only to develop a differentiated technology in record time, but also to successfully transition from R&D to Sales. We are currently present in relevant markets in EU and paving the way to launch in the U.S. in the mid term. Noteworthy, since our main call point is the ENT, CAVI-T prepares the ground for our upcoming ARIS platform. | $8.2M / Sep 05, 2025 | ||
| Hemerion is focused on creating innovative cancer treatments. The focus is on cutting-edge methods to treat glioblastoma, the most prevalent and dangerous primary brain tumour. | $2.8M / Series A / May 22, 2025 | ||
| Ensweet is a telemedicine platform intended to offer telerehabilitation services to patients. They offer equipment so that everyone can exercise whenever possible, enabling patients to have accessible rehabilitation. | $3.4M / Seed / May 20, 2025 | ||
| BiblioOnDemand is a provider of digital library services that offer a diverse selection of ebooks and audiobooks. | $1.1M / Seed / Nov 05, 2024 | ||
| Cellaven develops affordable, compact automation for cell culture to accelerate lab research. | $3M / Seed / Jul 05, 2024 | ||
| Karyon Food is an IT software company that provides online tool for retailer and SME's to manage sales data. | $433.7K / Seed / Apr 05, 2024 | ||
| Nestor is a digital assistant that simplifies document collection, providing a secure third party to enhance professional exchanges. Nestor allows companies to securely communicate with customers, transmit documents, and automatically delete data when legal retention periods expire. Nestor's innovative vision aims to protect companies'information systems by eliminating the need to store personal data. | $1.3M / Seed / Mar 22, 2024 | ||
| See all 44 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Finovam Gestion invest in?
Finovam Gestion invests primarily in Software, Information Technology and Medical startups, most often at Seed and Series A stage. Most of the 44 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Finovam Gestion's check size?
Finovam Gestion typically joins rounds of $513k–$3.4M at Seed and $530k–$18M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Finovam Gestion participates in.
How do I contact Finovam Gestion?
Public channels for Finovam Gestion include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Finovam Gestion?
The team at Finovam Gestion includes Anthony Daccache (Seed Capital Developer - Seed Investment Fund) and Hélène Cannard (Member of executive management). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
